Ozgur Aslan1, Metin Demir2, Mehmet Koseoglu3. 1. Clinical Chemistry Laboratory, Diyarbakır Maternity and Children Hospital, Diyarbakir, Turkey. ozguraslan44@yahoo.com. 2. Clinical Chemistry Laboratory, Gaziantep. Dr Ersin Arslan State Hospital, Gaziantep, Turkey. 3. Department of II. Biochemistry and Clinical Biochemistry, Ataturk Training and Research Hospital, Izmir, Turkey.
Abstract
BACKGROUND: This study was designed to determine the diagnostic role of urinary kidney injury molecule (KIM)-1 levels in renal damage in patients with type 2 diabetes mellitus according to the urinary albumin/creatinine ratio. METHODS: Patients with type 2 diabetes mellitus admitted to different polyclinics in our hospital enrolled in the study and were subdivided into three groups according to albumin/creatinine ratio - normalbuminuric (n: 20); microalbuminuric (n: 20); albuminuric (n: 18) - and compared with the control group. Urine albumin was analyzed using the immunoturbidimetric method (Architect C16000, Abbott Diagnostics). uKIM-1 was determined using a commercially available enzyme-linked immunosorbent assay test kit (USCN Life Science, Hankou, Wuhan, China). One-sample Kolmogorov-Smirnov test, Spearman correlation and Kruskal-Wallis non-parametric tests were performed. Post hoc comparisons were made using Bonferroni-corrected Mann-Whitney U tests. RESULTS: The differences between the controls and normalbuminuric, microalbuminuric and albuminuric groups were highly significant for KIM-1. Positive correlation was found between KIM-1 and urine microalbumin-urine microalbumin/creatinine (r = 0.479 P < 0.001; r = 0. 400, P < 0.001; respectively). CONCLUSION: In our study, KIM-1 levels were significantly different suggesting that urinary KIM-1 levels may be an early marker in patients with diabetic nephropathy. J. Clin. Lab. Anal. 00:1-6, 2016.
BACKGROUND: This study was designed to determine the diagnostic role of urinary kidney injury molecule (KIM)-1 levels in renal damage in patients with type 2 diabetes mellitus according to the urinary albumin/creatinine ratio. METHODS:Patients with type 2 diabetes mellitus admitted to different polyclinics in our hospital enrolled in the study and were subdivided into three groups according to albumin/creatinine ratio - normalbuminuric (n: 20); microalbuminuric (n: 20); albuminuric (n: 18) - and compared with the control group. Urine albumin was analyzed using the immunoturbidimetric method (Architect C16000, Abbott Diagnostics). uKIM-1 was determined using a commercially available enzyme-linked immunosorbent assay test kit (USCN Life Science, Hankou, Wuhan, China). One-sample Kolmogorov-Smirnov test, Spearman correlation and Kruskal-Wallis non-parametric tests were performed. Post hoc comparisons were made using Bonferroni-corrected Mann-Whitney U tests. RESULTS: The differences between the controls and normalbuminuric, microalbuminuric and albuminuric groups were highly significant for KIM-1. Positive correlation was found between KIM-1 and urine microalbumin-urine microalbumin/creatinine (r = 0.479 P < 0.001; r = 0. 400, P < 0.001; respectively). CONCLUSION: In our study, KIM-1 levels were significantly different suggesting that urinary KIM-1 levels may be an early marker in patients with diabetic nephropathy. J. Clin. Lab. Anal. 00:1-6, 2016.
Authors: Mark E Molitch; Ralph A DeFronzo; Marion J Franz; William F Keane; Carl Erik Mogensen; Hans-Henrik Parving; Michael W Steffes Journal: Diabetes Care Date: 2004-01 Impact factor: 19.112
Authors: José Antonio M de Carvalho; Etiane Tatsch; Bruna S Hausen; Yãnaí S Bollick; Maria B Moretto; Thiago Duarte; Marta M M F Duarte; Sílvia W K Londero; Melissa O Premaor; Fabio V Comim; Joris R Delanghe; Rafael N Moresco Journal: Clin Biochem Date: 2015-10-27 Impact factor: 3.281
Authors: Femke Waanders; Mirjan M van Timmeren; Coen A Stegeman; Stephan J L Bakker; Harry van Goor Journal: J Pathol Date: 2010-01 Impact factor: 7.996
Authors: M von Eynatten; M Baumann; U Heemann; D Zdunek; G Hess; P P Nawroth; A Bierhaus; P M Humpert Journal: Eur J Clin Invest Date: 2009-11-11 Impact factor: 4.686
Authors: Malgorzata Kasztan; Brandon M Fox; Jeffrey D Lebensburger; Kelly A Hyndman; Joshua S Speed; Jennifer S Pollock; David M Pollock Journal: Blood Adv Date: 2019-05-14